LKLatif Korkmaz

Latif Korkmaz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Latif Korkmaz has a total of 5 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Monte Carlo simulation for the interaction characteristics of gamma-rays with several tissues and water as a tissue substitute

    by Urkiye Akar Tarim, Orhan Gurler, Latif Korkmaz

    The study aimed to present an alternative method that is applicable to develop the perfect tissue-equivalent material that is completely tissue equivalent in all of its gamma-ray interaction properties. In this work, a Monte Carlo code has been written and simulations have been performed to achieve the gamma-ray interaction data details for the selected body tissues and tissue substitutes quoted from the ICRU Reports that are required for accurate assessment in radiotherapy, radiodiagnosis patient dosimetry and radiation protection. Accurate values of the linear attenuation coefficient for the selected absorber samples have been calculated by using simulation outputs. A comparison has been made with theoretical and experimental data that has appeared in the literature. The results presented in the tables, appear to be close to each other, which shows that the simulation procedure used in this work is suitable for use in such kinds of studies. The results reported here imply that the method presented in this study is important and reliable in providing convenient substitutes for certain treatment procedures for phantoms, radiation detectors, detector walls and tissue-equivalent proportional counters.


  • Were We Able to Reduce Cardiac Doses in Breast Cancer Radiotherapy Over Time?

    by Pelin Altınok, Latif Korkmaz, Ayse Altınok, Nuran Beşe

    In this study, we aimed to review the heart and left coronary artery doses over the years in patients who received breast cancer radiotherapy (RT). A total of 436 breast cancer patients of 2 RT centers treated between the years 2010 and 2018 were included. The mean heart doses (HeartDmean-HDM) and left coronary artery mean doses (LDM) were analyzed using nonparametric tests. The conventional RT (CRT) was 50 Gy/2 Gy in 5 weeks, and the hypofractionated RT (HRT) was 40.05 Gy/2.67 Gy in 3 weeks. Boost was applied as 10–16 Gy/2 Gy for CRT and 10 Gy/2.5 Gy for HRT. An equivalent conventional total dose of 2 Gy/fraction (EQD2) was taken into account for HRT. HDM was 107±104 cGy, and LDM was 288±209 cGy for the entire group. HDM was significantly lower in patients with breast-conserving surgery (99±94 cGy) than that in those with mastectomy (128±124 cGy) (p<0.001). Field-in-field intensity-modulated RT technique significantly reduced the doses compared to volumetric applications (104±95 cGy vs 141±38 cGy; p = 0.002). HDM was significantly increased with lymphatic RT (132±58 cGy vs 112±115 cGy; p<0.001). The addition of internal mammary volumes significantly increased HDM (p<0.001). No significant effect of boost was observed (p = 0.96). For both CRT and HRT regimens, HDM values were significantly lower after the year 2014 (right side p<0.001, left side p = 0.01). In the left side CRT, HDM was 1.74 Gy before 2014 and 1.3 Gy after 2014 and 1.0 and 1.19 Gy, respectively, for the right side. All efforts to reduce the cardiac doses will likely reduce long-term side effects.